Nahdi Medical Co. posted a net profit of SAR 244.3 million in Q1 2023, a 3% increase from SAR 237.5 million a year earlier.
| Item | Q1 2022 | Q1 2023 | Change |
|---|---|---|---|
| Revenues | 2,079.49 | 2,105.04 | 1.2 % |
| Gross Income | 851.73 | 889.20 | 4.4 % |
| Operating Income | 255.15 | 263.20 | 3.2 % |
| Net Income | 237.51 | 244.34 | 2.9 % |
| Average Shares | 130.00 | 130.00 | - |
| EPS (Riyals) | 1.83 | 1.88 | 2.9 % |
| Item | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Revenues | 2,138.24 | 2,105.04 | (1.6 %) |
| Gross Income | 856.31 | 889.20 | 3.8 % |
| Operating Income | 148.89 | 263.20 | 76.8 % |
| Net Income | 127.99 | 244.34 | 90.9 % |
| Average Shares | 130.00 | 130.00 | - |
| EPS (Riyals) | 0.98 | 1.88 | 90.9 % |
The positive performance was attributed to an increase of 1.2% year-on-year (YoY) in revenue to SAR 2.1 billion on growth in retail and healthcare business segments.
Gross profit increased by 4.1% YoY in Q1 2023 to SAR 886.9 million, driven by sales growth, private label growth, and positive product mix. As a result, the gross margin improved by 1.2% to 42.1% of revenue in Q1 from 41.0% in Q1 2022.
On the other hand, OpEx rose by 5.4% in Q1 2023 to SAR 629 million, mainly to support the business growth in line with the company's business plan.
Sequentially, net profit rose 90.9% from SAR 127.99 million in Q4 2022.
Shareholders’ equity, excluding minority interest, stood at SAR 2.08 billion as of March 31, 2023, compared to SAR 1.84 billion a year earlier.
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}